Related content

Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma

By Sugawara Mitsuhiro  

Esophagus, Vol. 10, Iss. 2, 2013-06 ,pp. : 65-69

Springer Publishing Company

Access to resources Recommend Favorite

Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus

By Yoshida Takahiro  

Esophagus, Vol. 7, Iss. 2, 2010-06 ,pp. : 95-100

Springer Publishing Company

Access to resources Recommend Favorite

Induction Chemotherapy with Docetaxel/Cisplatin/5-Fluorouracil for Patients with Node-Positive Esophageal Cancer

By  

Digestion, Vol. 83, Iss. 3, 2011-01 ,pp. : 146-152

Karger

Access to resources Recommend Favorite

Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) Regimen as an Adjuvant Chemotherapy in the Treatment of Advanced Jejunal Adenocarcinoma: A Report of 2 Cases

By  

Medical Principles and Practice, Vol. 17, Iss. 6, 2008-10 ,pp. : 496-499

Karger

Access to resources Recommend Favorite

Neoadjuvant chemoradiotherapy followed by esophagectomy versus definitive chemoradiotherapy in resectable stage II/III (T1-3N0, 1M0) esophageal squamous cell carcinoma

By Nagata Matsuo   Yamamoto Hiroshi   Takiguchi Nobuhiro   Kainuma Osamu   Cho Akihiro   Mori Mikito   Narumoto Sohichi   Asano Takehide   Hatano Kazuo  

Esophagus, Vol. 3, Iss. 3, 2006-09 ,pp. : 105-111

Springer Publishing Company

Access to resources Recommend Favorite